{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T03:28:33Z","timestamp":1761017313891,"version":"build-2065373602"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.seizure.2020.10.025","type":"journal-article","created":{"date-parts":[[2020,12,15]],"date-time":"2020-12-15T02:24:52Z","timestamp":1607999092000},"page":"249-250","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Carbamazepine and me!"],"prefix":"10.1016","volume":"83","author":[{"given":"Martin J.","family":"Brodie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.seizure.2020.10.025_bib0005","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/clpt.1980.115","article-title":"Rifampicim and vitamin D metabolism","volume":"27","author":"Brodie","year":"1980","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.seizure.2020.10.025_bib0010","first-page":"363","article-title":"Does rifampicim increase serum levels of testosterone and oestradiol by influencing sex hormone binding capacity?","volume":"30","author":"Brodie","year":"1981","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.seizure.2020.10.025_bib0015","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/j.1365-2125.1984.tb02352.x","article-title":"Changes in circulating androgens during short-term carbamazepine therapy","volume":"17","author":"Connell","year":"1983","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.seizure.2020.10.025_bib0020","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/BF00542140","article-title":"Changes in circulating thyroid hormones during short term hepatic enzyme induction with carbamazepine","volume":"26","author":"Connell","year":"1984","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.seizure.2020.10.025_bib0025","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/j.1528-1157.1987.tb04220.x","article-title":"Intradose and circadian variation in circulating carbamazepine and its epoxide in epileptic patients: a consequence of autoinduction of metabolism","volume":"28","author":"Macphee","year":"1987","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2020.10.025_bib0030","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1136\/bmj.300.6730.978","article-title":"Managing seizures in the casualty department","volume":"30","author":"McKee","year":"1990","journal-title":"Br Med J"},{"key":"10.1016\/j.seizure.2020.10.025_bib0035","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0140-6736(95)90581-2","article-title":"The UK lamotrigine\/carbamazepine monotherapy trial group Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy","volume":"345","author":"Brodie","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.seizure.2020.10.025_bib0040","first-page":"257","article-title":"The UK lamotrigine elderly study group multi-centre double-blind randomised comparison between lamotrigine and carbamazepine with elderly patients with newly diagnosed epilepsy","volume":"40","author":"Brodie","year":"1999","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.seizure.2020.10.025_bib0045","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1212\/01.wnl.0000252941.50833.4a","article-title":"Comparison of levetiracetam and carbamazepine nonotherapy in newly diagnosed epilepsy","volume":"67","author":"Brodie","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2020.10.025_bib0050","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1136\/jnnp.51.7.929","article-title":"Concentration effect relationships with carbamazepine and its epoxide on psychomotor and cognitive function in epileptic patients","volume":"51","author":"Gillham","year":"1988","journal-title":"J Neurol Neurosurg Psychiat"},{"key":"10.1016\/j.seizure.2020.10.025_bib0055","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1053\/seiz.2000.0428","article-title":"A double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health-related quality of life as an outcome measure","volume":"9","author":"Gillham","year":"2000","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2020.10.025_bib0060","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1528-1167.2012.03671.x","article-title":"Enzyme induction with antiepileptic drugs: cause for concern?","volume":"54","author":"Brodie","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2020.10.025_bib0065","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s00204-008-0332-8","article-title":"Inhibition and induction of human cytochromes P450) enzymes: status","volume":"82","author":"Pelkonen","year":"2008","journal-title":"Arch Toxicol"},{"key":"10.1016\/j.seizure.2020.10.025_bib0070","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.bcp.2010.04.034","article-title":"Function and transcriptional regulation of adult human hepatic UDP-glucuronosyl-transferases (UGTs)-mechanisms responsible for individual variation of UGT levels","volume":"80","author":"Bock","year":"2010","journal-title":"Biochip Pharmacol"},{"key":"10.1016\/j.seizure.2020.10.025_bib0075","first-page":"964","article-title":"Bone health in people with epilepsy: is it impaired and what are the risk factors?","volume":"20","author":"Pack","year":"2008","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2020.10.025_bib0080","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1111\/j.0013-9580.2004.18804.x","article-title":"Fracture risk associated with use of antiepileptic drugs","volume":"45","author":"Vestergaard","year":"2004","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2020.10.025_bib0085","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.yebeh.2006.11.007","article-title":"A 6-month longitudinal study of bone mineral density with antiepileptic drug monotherapy","volume":"10","author":"Kim","year":"2007","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2020.10.025_bib0090","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1212\/01.wnl.0000178988.78039.40","article-title":"Differential effects of antiepileptic drugs on sexual function and hormones in men with epilepsy","volume":"65","author":"Herzog","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2020.10.025_bib0095","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.yebeh.2005.01.004","article-title":"Sexual dysfunction, sex steroid hormone abnormalities and depression in women with epilepsy treated with antiepileptic drugs","volume":"6","author":"Morrell","year":"2005","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2020.10.025_bib0100","first-page":"2798","article-title":"Increased risk and worse prognosis of myocardial infarcation in patients with prior hospitalisation for epilepsy","volume":"132","author":"Jansky","year":"2009","journal-title":"Stockholm Heart Epidemiol Program Brain"},{"key":"10.1016\/j.seizure.2020.10.025_bib0105","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1212\/WNL.0000000000002984","article-title":"Excess mortality and hospitalised morbidity in newly treated patients","volume":"87","author":"Chen","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2020.10.025_bib0110","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/epi.16420","article-title":"Hyperlipidemia in patients newly treated with anticonvulsants: a population study","volume":"61","author":"Minzter","year":"2020","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2020.10.025_bib0115","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1528-1167.2011.03316.x","article-title":"Effect of long-term antiepileptic drug monotherapy on vascular risk factors and arteriosclerosis","volume":"53","author":"Chuang","year":"2012","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2020.10.025_bib0120","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/pds.2186","article-title":"Effect of epilepsy and selected antiepileptic drugs on risk of myocardial infarction, stroke, and death in patients with or without previous stroke: a nationwide cohort study","volume":"20","author":"Oleson","year":"2011","journal-title":"Pharmacol Epidemiol Drug Saf"},{"key":"10.1016\/j.seizure.2020.10.025_bib0125","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/S1474-4422(20)30035-1","article-title":"30 years of second generation antiseizure medicines: impact and future perspectives","volume":"19","author":"Perucca","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.seizure.2020.10.025_bib0130","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1001\/jamaneurol.2017.3949","article-title":"Treatment outcomes in newly diagnosed epilepsy with controlled and new antiepileptic drugs: a 30-year longitudinal cohort study","volume":"75","author":"Chen","year":"2018","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.seizure.2020.10.025_bib0135","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1001\/jamaneurol.2020.0032","article-title":"Prediction of tolerability to antiepileptic drugs in newly diagnosed epilepsy: a 30-year follow-up study","volume":"72","author":"Alsfouk","year":"2020","journal-title":"JAMA Neurol"}],"container-title":["Seizure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131120303435?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131120303435?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T01:58:32Z","timestamp":1761011912000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131120303435"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":27,"alternative-id":["S1059131120303435"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2020.10.025","relation":{},"ISSN":["1059-1311"],"issn-type":[{"type":"print","value":"1059-1311"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Carbamazepine and me!","name":"articletitle","label":"Article Title"},{"value":"Seizure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2020.10.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 British Epilepsy Association. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}